Uppsala 31th May 2018
New positive results from animal studies
Nanexa has received results from a one week long animal study conducted during May. The study was conducted on rats injected subcutaneously with a model drug that was provided with a further development of Nanexa’s drug delivery system PharmaShell®.
The new results show interesting and positive properties of PharmaShell® during the first time after administration.
Nanexa’s CEO David Westberg comments:
With the new animal study results, we further confirm that PharmaShell® is a drug delivery system with unique features. We are able to control several parameters that are important for creating effective and safe drugs. The properties of PharmaShell®, as demonstrated by the study, are also valuable for the drug project aimed at oncology, which we will run on our own.
I look forward to communicating the new results with the pharmaceutical companies we are in contact with.
For further information:
Nanexa AB (publ)
David Westberg, VD
Phone: +46 709 42 83 03
E mail: email@example.com
About Nanexa AB (publ)
Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a